The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution
Research article published in Anaesthesia and intensive care (2014)
Abstract
Heparin-induced thrombocytopenia is a serious complication of heparin use. Treatment includes discontinuation of heparin and initiation of alternative anticoagulation therapy. In extracorporeal membrane oxygenation anticoagulation is mandatory, and direct thrombin inhibitors (DTIs) have been approved in these cases. However, the use and monitoring of DTIs in extracorporeal membrane oxygenation patients is not well described. DTI use is also complicated by the imprecision of available monitoring tests and currently recommended dosing has been shown to result in a supratherapeutic anticoagulative state. This case report describes the successful use of the DTI argatroban as an alternative anticoagulant in a patient with heparin-induced thrombocytopenia requiring extracorporeal membrane oxygenation support.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Peer-reviewed pharmacology and drug-development research relevant to antithrombotic agents and leech-derived compounds. Indexed in PubMed and verified against the NCBI record.
Why This Matters for Hirudotherapy
This case report describes the successful use of the direct thrombin inhibitor argatroban as an alternative anticoagulant in a single patient who developed heparin-induced thrombocytopenia while requiring extracorporeal membrane oxygenation (ECMO); the abstract cautions that direct thrombin inhibitor use in ECMO is poorly characterized, monitoring tests are imprecise, and recommended dosing can produce a supratherapeutic anticoagulant state. Its connection to hirudotherapy is class-level: argatroban shares the direct, antithrombin-independent thrombin-inhibition mechanism of leech-derived hirudin, making this a window into how that pharmacologic class is monitored and dosed in critically ill patients. Caveat: a single-patient case report is the lowest tier of clinical evidence — it illustrates feasibility and a dosing/monitoring warning, not efficacy, and it concerns a synthetic agent rather than medicinal-leech therapy.
Citation
The dosing and monitoring of argatroban for heparin-induced thrombocytopenia during extracorporeal membrane oxygenation: a word of caution.
Phillips et al. · Anaesthesia and intensive care, 2014
Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026